Splash Pharmaceuticals Announces Clinical Trial Presentation at the 2018 American Society of Clinical Oncology Annual Meeting

Abstract presentation of ongoing clinical trial

SAN DIEGO--()--Splash Pharmaceuticals, Inc. (“Splash”), a closely held private biopharmaceutical company that develops novel cancer therapies, announced the presentation of an abstract related to the clinical trial of SPL-108 in platinum-resistant ovarian cancer patients. The Phase I trial is being conducted at Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, and the abstract will be presented by its first author Dr. Eugenia Girda, a member of the Institute’s Gynecologic Oncology Program.

Presentation Details:
American Society of Clinical Oncology (ASCO) 2018 Annual meeting in Chicago, IL.
Poster Discussion: Monday June 4, 2018 from 1:15 p.m. – 4:45 p.m. (CDT)
An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.
Poster Presentation: Abstract #TPS5608, Poster Board #331a, Hall A

About Splash Pharmaceuticals

Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs. For more information, please visit www.splashpharma.com.


for Splash Pharmaceuticals, Inc.
Beth Nelson

Recent Stories

RSS feed for Splash Pharmaceuticals